Fortitude Family Office’s Enanta Pharmaceuticals ENTA Stock Holding History

Fortitude Family Office’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62K	Buy	+111	New	+$1.49K	﹤0.01%	1565

Other funds holding ENTA

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Fortitude Family Office's ENTA Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 111 shares worth $1.62K. The stake represents ﹤0.01% of the portfolio and ranks #1565 among its holdings.

15 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Fortitude Family Office held 111 shares of Enanta Pharmaceuticals worth $1.62K as of Q2 2026.
Enanta Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1565 holding.
15 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.